Title:Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article

VOLUME: 20 ISSUE: 10

Author(s):Mohammad Yassin Zamanian, Małgorzata Kujawska, Marjan Nikbakhtzadeh, Amin Hassanshahi, Soudeh Ramezanpour , Zahra Kamiab and Gholamreza Bazmandegan*

Affiliation:Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Department of Toxicology, Poznan University of Medical Sciences, Dojazd 30, Poznan, 60-631, Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Department of Physiology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Shohada Hospital, Bandar Gaz, Golestan University of Medical Sciences, Bandar Gaz, Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan

Keywords:Anti-inflammatory, antioxidant, carvacrol, neurological diseases, neuroprotection, TRPC1, TRPM7.

Abstract:

Background and Objective: Neurological diseases are becoming a significant problem worldwide, with the elderly at a higher risk of being affected. Several researchers have investigated the neuroprotective effects of Carvacrol (CAR) (5-isopropyl-2-methyl phenol). This review systematically surveys the existing literature on the impact of CAR when used as a neuroprotective agent in neurological diseases.

Methods: The systematic review involved English articles published in the last ten years obtained from PubMed, Google Scholar, and Scopus databases. The following descriptors were used to search the literature: “Carvacrol” [Title] AND “neuroprotective (neuroprotection)” [Title] OR “stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, seizure, epilepsy [Title].

Results: A total of 208 articles were retrieved during the search process, but only 20 studies met the eligibility criteria and were included for review. A total of 20 articles were identified, in which the efficacy of CAR was described in experimental models of stroke, traumatic brain injury, Parkinson’s disease, Alzheimer’s disease, epilepsy, and seizure, through motor deficits improvements in neurochemical activity, especially antioxidant systems, reducing inflammation, oxidative stress and apoptosis as well as inhibition of TRPC1 and TRPM7.

Conclusion: The data presented in this study support the beneficial impact of CAR on behavioural and neurochemical deficits. CAR benefits accrue because of its anti-apoptotic, antioxidant, and anti- inflammatory properties. Therefore, CAR has emerged as an alternative treatment for neurological disorders based on its properties.